全文获取类型
收费全文 | 3046篇 |
免费 | 207篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 80篇 |
妇产科学 | 78篇 |
基础医学 | 514篇 |
口腔科学 | 262篇 |
临床医学 | 317篇 |
内科学 | 621篇 |
皮肤病学 | 40篇 |
神经病学 | 315篇 |
特种医学 | 30篇 |
外科学 | 192篇 |
综合类 | 19篇 |
一般理论 | 2篇 |
预防医学 | 331篇 |
眼科学 | 48篇 |
药学 | 196篇 |
中国医学 | 14篇 |
肿瘤学 | 175篇 |
出版年
2024年 | 8篇 |
2023年 | 53篇 |
2022年 | 96篇 |
2021年 | 170篇 |
2020年 | 111篇 |
2019年 | 122篇 |
2018年 | 123篇 |
2017年 | 94篇 |
2016年 | 117篇 |
2015年 | 109篇 |
2014年 | 136篇 |
2013年 | 162篇 |
2012年 | 270篇 |
2011年 | 308篇 |
2010年 | 168篇 |
2009年 | 124篇 |
2008年 | 222篇 |
2007年 | 180篇 |
2006年 | 184篇 |
2005年 | 162篇 |
2004年 | 107篇 |
2003年 | 93篇 |
2002年 | 75篇 |
2001年 | 12篇 |
2000年 | 6篇 |
1999年 | 14篇 |
1998年 | 8篇 |
1997年 | 4篇 |
1996年 | 6篇 |
1995年 | 5篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有3266条查询结果,搜索用时 0 毫秒
61.
62.
Elymir S Galvis-Garc a Sergio Sobrino-Coss o Arturo Reding-Bernal Yesica Contreras-Mar n Karina Sol rzano-Acevedo Patricia Gonz lez-Zavala Rosa M Quispe-Siccha 《World journal of gastroenterology : WJG》2020,26(34):5169-5180
BACKGROUND Endoscopic ultrasound(EUS) and endoscopic ultrasound elastography(EUS-E) simulation lessens the learning curve; however, models lack realism, diminishing competitiveness.AIM To standardize the mechanical properties of polyvinyl alcohol(PVA) hydrogel for simulating organs and digestive lesions.METHODS PVA hydrogel(Sigma Aldrich, degree of hydrolysis 99%) for simulating EUS/EUS-E lesions was investigated in Unidad de Investigación y Desarrollo Tecnológico at Hospital General de México "Dr. Eduardo Liceaga", Mexico City. We evaluated physical, contrast, elasticity and deformation coefficient characteristics in lesions, applying Kappa's concordance and satisfaction questionnaire(Likert 4-points).RESULTS PVA hydrogel showed stable mechanical properties. Density depended on molecular weight(MW) and concentration(C). PVA bblocks with the greatest density showed lowest tensile strength(r =-0.8, P = 0.01). Lesions were EUSgraphically visible. Homogeneous and heterogeneous examples were created from PVA blocks or PVA phantoms, exceeding(MW_2 = 146000-186000, C_9 = 15% and C_(10) = 20%) with a density under(MW_1 = 85000-124000, C_1 = 7% and C_2 = 9%). We calculated elasticity and deformation parameters of solid(blue) areas, contrasting with the norm(Kappa = 0.8; high degree of satisfaction).CONCLUSION PVA hydrogels were appropriate for simulating organs and digestive lesions using EUS/EUS-E, facilitating practice and reducing risk. Repetition amplified skills, while reducing the learning curve. 相似文献
63.
64.
Andreas Janzer Natalie J. German Karina N. Gonzalez-Herrera John M. Asara Marcia C. Haigis Kevin Struhl 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(29):10574-10579
Metformin, a first-line diabetes drug linked to cancer prevention in retrospective clinical analyses, inhibits cellular transformation and selectively kills breast cancer stem cells (CSCs). Although a few metabolic effects of metformin and the related biguanide phenformin have been investigated in established cancer cell lines, the global metabolic impact of biguanides during the process of neoplastic transformation and in CSCs is unknown. Here, we use LC/MS/MS metabolomics (>200 metabolites) to assess metabolic changes induced by metformin and phenformin in an Src-inducible model of cellular transformation and in mammosphere-derived breast CSCs. Although phenformin is the more potent biguanide in both systems, the metabolic profiles of these drugs are remarkably similar, although not identical. During the process of cellular transformation, biguanide treatment prevents the boost in glycolytic intermediates at a specific stage of the pathway and coordinately decreases tricarboxylic acid (TCA) cycle intermediates. In contrast, in breast CSCs, biguanides have a modest effect on glycolytic and TCA cycle intermediates, but they strongly deplete nucleotide triphosphates and may impede nucleotide synthesis. These metabolic profiles are consistent with the idea that biguanides inhibit mitochondrial complex 1, but they indicate that their metabolic effects differ depending on the stage of cellular transformation.Altered metabolism is a hallmark of malignantly transformed cells. Cancer risk is linked to metabolic syndrome, a disease state that includes obesity, type 2 diabetes, high cholesterol, and atherosclerosis. Retrospective studies of type 2 diabetes patients treated with metformin, the most widely prescribed antidiabetic drug, show a strong correlation between drug intake and reduced tumor incidence or reduced cancer-related deaths (1–4).In the breast lineage, metformin inhibits growth of cancer cell lines (5–7), blocks transformation in a Src-inducible cell system (8, 9), and selectively inhibits the growth of cancer stem cells (CSCs) (8). As a consequence of its selective effects on CSCs, combinatorial therapy of metformin and standard chemotherapeutic drugs (doxorubicin, paclitaxel, and cisplatin) increases tumor regression and prolongs remission in mouse xenografts (8, 10). In addition, metformin can decrease the chemotherapeutic dose for prolonging tumor remission in xenografts involving multiple cancer types (10).Phenformin, a related biguanide and formerly used diabetes drug, acts as an anticancer agent in tumors including lung, lymphoma, and breast cancer with a greater potency than metformin. Phenformin mediates antineoplastic effects at a lower concentration than metformin in cell lines, a PTEN-deficient mouse model, breast cancer xenografts, and drug-induced mitochondrial impairment (11–14). The chemical similarities of these biguanides, as well as their similar effects in diabetes and cancer, have led to the untested assumption that phenformin is essentially a stronger version of metformin.In a Src-inducible model of cellular transformation and CSC formation, multiple lines of evidence suggest that metformin inhibits a signal transduction pathway that results in an inflammatory response (15). In the context of atherosclerosis, metformin inhibits NF-κB activation and the inflammatory response via a pathway involving AMP kinase (AMPK) and the tumor suppressor PTEN (16, 17). As metformin alters energy metabolism in diabetics, we speculated that metformin might block a metabolic stress response that stimulates the inflammatory pathway (15). However, very little is known about the metabolic changes that inhibit the inflammatory pathway.Previous studies on metformin-induced metabolic effects in cancer have focused on single metabolic alterations or pathways in already established cancer cell lines. Metformin leads to activation of AMPK, which plays a key role in insulin signaling and energy sensing (18). Metformin can reduce protein synthesis via mTOR inhibition (19). In addition, metformin may directly impair mitochondrial respiration through complex I inhibition and has been described to boost glycolysis as a compensation mechanism (14, 20). In this regard, lactic acidosis can be a side effect of metformin and phenformin treatment of diabetic patients, presumably because inhibition of complex I prevents NADH oxidation, thereby leading to a requirement for cytosolic NADH to be oxidized by the conversion of pyruvate to lactate. There is some knowledge about the metabolic effects of metformin (21, 22), but very little is known about the specific metabolic alterations linking biguanides to inhibition of neoplastic transformation.Here, we perform a metabolomic analysis on the effects of metformin and phenformin in a Src-inducible model of transformation and in CSCs. This inducible model permits an analysis of the transition from nontransformed to transformed cells in an isogenic cell system and hence differs from analyses of already established cancer cell lines. We studied CSCs to address why this population, which is resistant to standard chemotherapeutics and hypothesized to be a major reason for tumor recurrence, is selectively inhibited by metformin. Our results indicate the metabolic effects of metformin and phenformin are remarkably similar to each other, with only a few differences. Both biguanides dramatically decrease tricarboxylic acid (TCA) cycle intermediates in the early stages of transformation, and they inhibit the boost in select glycolytic intermediates that normally occurs with transformation along with increases in glycerol 3-phosphate and lactate, which are metabolites branching from glycolysis. Unexpectedly, in CSCs, biguanides have only marginal effects on glycolytic and TCA cycle metabolites, but they severely decrease nucleotide triphosphates. These detailed metabolic analyses provide independent support for the idea that metformin inhibits mitochondrial complex 1 (14, 20), and they indicate that the metabolic effects of biguanides depend on the stage of the cellular transformation. 相似文献
65.
Timothy R. Leahy Michelle Goode Paul Lynam Patrick J. Gavin Karina M. Butler 《Influenza and other respiratory viruses》2014,8(3):360-366
Design
Children with HIV are especially susceptible to complications from influenza infection, and effective vaccines are central to reducing disease burden in this population. We undertook a prospective, observational study to investigate the safety and immunogenicity of the inactivated split-virion AS03-adjuvanted pandemic H1N1(2009) vaccine in children with HIV.Setting
National referral centre for Paediatric HIV in Ireland.Sample
Twenty four children with HIV were recruited consecutively and received two doses of the vaccine. The serological response was measured before each vaccine dose (Day 0 and Day 28) and 2 months after the booster dose. Antibody titres were measured using a haemagglutination inhibition (HAI) assay. Seroprotection was defined as a HAI titre ≥ 1:40; seroconversion was defined as a ≥ fourfold increase in antibody titre and a postvaccination titre ≥ 1:40.Main outcome measures
The seroconversion rates after prime and booster doses were 75% and 71%, respectively. HIV virological suppression at the time of immunization was associated with a significantly increased seroconversion rate (P = 0·009), magnitude of serological response (P = 0·02) and presence of seroprotective HAI titres (P = 0·017) two months after the booster dose. No other factor was significantly associated with the seroconversion/seroprotection rate. No serious adverse effects were reported. Vaccination had no impact on HIV disease progression. The AS03-adjuvanted pandemic H1N1 vaccine appears to be safe and immunogenic among HIV-infected children. A robust serological response appears to be optimized by adherence to a HAART regimen delivering virological suppression. 相似文献66.
Igor Bastos Polonio Milena Marques Pagliareli Acencio Rogério Pazetti Francine Maria de Almeida Bárbara Soares da Silva Karina Aparecida Bonifácio Pereira Rogério Souza 《Jornal brasileiro de pneumologia》2014,40(4):421-424
We assessed the effects of lodenafil on hemodynamics and inflammation in the rat
model of monocrotaline-induced pulmonary hypertension (PH). Thirty male
Sprague-Dawley rats were randomly divided into three groups: control; monocrotaline
(experimental model); and lodenafil (experimental model followed by lodenafil
treatment, p.o., 5 mg/kg daily for 28 days) Mean pulmonary artery pressure (mPAP) was
obtained by right heart catheterization. We investigated right ventricular
hypertrophy (RVH) and IL-1 levels in lung fragments. The number of cases of RVH was
significantly higher in the monocrotaline group than in the lodenafil and control
groups, as were mPAP and IL-1 levels. We conclude that lodenafil can prevent
monocrotaline-induced PH, RVH, and inflammation. 相似文献
67.
68.
69.
Objectives
This study’s purpose was to evaluate the depth of cure (DOC) and the variation of mechanical properties with depth of two nano-hybrid resin-based composites (RBCs) containing a novel monomer composition based on dimer-acid derivatives (h-Da) or rather tricyclodecane–urethane structure (TCD-urethane) compared to three conventionally formulated nano-hybrid RBCs based on hardness-profile measurements.Materials and methods
Specimens were produced through different layering techniques (bulk, incremental) and curing times (10, 20, and 40?s). Mechanical properties (Vickers hardness (HV), modulus of elasticity (E)) were evaluated every 100?μm longitudinally throughout the bisected samples using an automatic micro-hardness indenter. DOC was determined as the depth at which the 80% hardness cutoff value in relation to the surface hardness was reached. Results were compared using one- and multiple-way ANOVA, Tukey HSD post-hoc test (α?=?0.05) and partial eta-squared statistic.Results
Increasing curing time resulted in a significant increase in DOC. Generally, the novel-formulated materials showed higher DOC values. “Curing time” and “material” showed the strongest effect on DOC. Starting in 4?mm depth, significantly higher HV and E was reached for incremental compared to bulk-curing technique. Values in 0.1 and 2?mm depth (bulk, incremental) as well as in 4?mm depth (incremental) were independent from curing time, while in greater depths, values generally increased with curing time. “Filling technique” and “material” performed the strongest influence on mechanical properties.Conclusions
Within the limits of this study, the novel-formulated RBCs showed better performance concerning DOC compared to conventional materials.Clinical relevance
For cavities deeper than 3?mm, all tested materials should be placed incrementally to ensure adequate polymerization. In large cavities (≥6?mm), the lowest increment should be cured at least 40?s. The novel-formulated RBCs might be cured in comparatively bigger increments. 相似文献70.
Günther Deuschl Michael Schüpbach Karina Knudsen Marcus O. Pinsker Philippe Cornu Jörn Rau Yves Agid Carmen Schade-Brittinger 《Parkinsonism & related disorders》2013,19(1):56-61
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for advanced Parkinson's disease (PD) with disabling motor complications. However, stimulation may be beneficial at an earlier stage of PD when motor fluctuations and dyskinesia are only mild and psychosocial competence is still maintained. The EARLYSTIM trial was conducted in patients with recent onset of levodopa-induced motor complications (≤3 years) whose social and occupational functioning remained preserved. This is called ‘early’ here. The study was a randomized, multicenter, bi–national pivotal trial with a 2 year observation period. Quality of life was the main outcome measure, and a video-based motor score was a blinded secondary outcome of the study. Motor, neuropsychological, psychiatric and psychosocial aspects were captured by established scales and questionnaires. The patient group randomized here is the earliest in the disease course and the youngest recruited in controlled DBS trials so far. The methodological innovation for DBS-studies of this study lies in novel procedures developed and used for monitoring best medical treatment, neurosurgical consistency, best management of stimulation programming, blinded video assessment of motor disability, and prevention of suicidal behaviors. 相似文献